BIOMARKER FOR MEASUREMENT OF RESPONSE AND PROGNOSIS OF TRIPLE-NEGATIVE BREAST CANCER TO ANTICANCER AGENT

摘要

The present disclosure discloses a biomarker capable of predicting the therapeutic response to anticancer agents and prognosis of triple-negative breast cancer patients, and the use thereof. A biomarker according to the present disclosure allows the provision of optimized personal therapeutic methods through correct personalized treatment, contributing to the quality and prolongation of life of patients.